PALMIRE cohort: phenotyping inflammatory lung diseases to enable personalized care
Official title: A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine
Run by CHU de Reims · NCT07274631 · Data updated 2026-11-12
This project will collect clinical, imaging, and biological data from adults with asthma, COPD, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, or interstitial lung disease to try to identify disease subtypes and markers that could guide more personalized care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 470 (estimated) |
| Sponsor | CHU de Reims Academic / other |
| Locations | 1 site (Reims) |
| Status | Recruiting |
| Started | September 15, 2025 |
| Main results expected | September 15, 2030 |
| Study ends | September 15, 2040 |
| Registry record updated | February 20, 2026 |
| Trial ID | NCT07274631 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) followed at the University Hospital of Reims with a confirmed diagnosis of asthma, COPD, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, or interstitial lung disease, as well as healthy volunteers for the control group.
✕Probably not a fit
People unable to give informed consent, those legally protected, or patients who cannot attend baseline or routine follow-up visits are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This monocentric, prospective cohort at the University Hospital of Reims will enroll adults with various chronic inflammatory lung diseases and healthy controls, with planned inclusion from July 2025 to July 2030. About 470 participants across disease groups (plus controls) will have detailed baseline data recorded and patients will be followed as part of usual care for up to 10 years. Collected data include demographics, disease history, symptoms, lung function tests, CT imaging, microbiology, pathology from respiratory samples when available, and exposure information. No experimental treatments are given; the project aims to link clinical, biological, and morphological features to underlying mechanisms and phenotypes.
Why it matters
Potential benefit: If successful, this work could help clinicians match treatments to each patient's disease phenotype and highlight new targets for therapy.
How similar studies have gone: Other longitudinal cohorts in asthma and COPD have successfully defined clinical and molecular phenotypes, but combining multiple inflammatory lung diseases in a single cohort for cross-disease phenotyping is less common.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Follow-up for one of the following conditions: asthma, COPD, bronchiectasis (DDB), cystic fibrosis (CF), primary ciliary dyskinesia (PCD), or interstitial lung diseases (ILD) * Healthy volunteers (controls) Exclusion Criteria: * Subjects protected by law (e.g., legal incapacity) * Any condition preventing informed consent or participation
Where it's running
-
Chu Reims
Reims, France Recruiting
Study contacts
- Study coordinator: Jeanne-Marie PEROTIN-COLLARD
- Email: jmperotin-collard@chu-reims.fr
- Phone: 03 10 73 67 63
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using smartphone technology to evaluate airway conditions
This study is testing if smartphone technology can help check lung health and spot breathing problems in both healthy people and those with asthma or COPD.
-
SELF-BREATHE: a self-guided online program to reduce chronic breathlessness in adults
This study will test whether SELF-BREATHE, a self-guided internet-based support program, can help adults with chronic breathlessness from lung or heart conditions breathe easier and feel less distressed.
-
Thermotherapy for persistent bacterial lung infections
This study is testing if regular heat therapy can help people with chronic lung infections get rid of stubborn bacteria that don’t respond to regular antibiotics.
-
Registry of healthy controls for respiratory diseases
This study is collecting health information from healthy volunteers to help researchers better understand respiratory diseases like asthma and COPD by comparing it to data from patients with these conditions.
-
Chronic Respiratory Disease Participant Engagement
This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.
-
How environmental fungal exposure affects asthma, ABPA, and bronchiectasis
This project will see if indoor and environmental fungal exposure is linked to disease control in adults with asthma, ABPA, or bronchiectasis and will compare findings to healthy adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.